Rise in geriatric population and influx of biologics are augmenting the paroxysmal nocturnal hemoglobinuria market demand. Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic disorder affecting nearly 20,000 people across the globe. It is characterized by three major manifestations, i.e. pancytopenia, persistent intravascular hemolysis, and thrombosis.
Companies spanning the paroxysmal nocturnal hemoglobinuria market report scope are working toward adoption of oral Iptacopan monotherapy in PNH. They are also exploring research opportunities regarding management of residual anemia in paroxysmal nocturnal hemoglobinuria.
Influx of injectors approved by the regulatory bodies is expected to open new arenas for the stakeholders to map strategies for dealing with paroxysmal nocturnal hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria (PNH) means a rare blood disorder that occurs when one’s immune system partly attacks as well as damages the platelets and red blood cells. If left untreated, PNH is likely to result in chronic kidney disease or thrombosis (blood clots) or hemolytic anemia.
The symptom of PNH constitutes dark/brown/red urine early morning or during late night. ‘Paroxysmal’ means ‘sudden’, ‘nocturnal’ means ‘night’, and ‘hemoglobinuria’ means pee stained with blood.
Soliris (eculizumab) is the first drug approved for treating patients suffering from PNH by curtailing hemolysis. This monoclonal antibody reduces/terminates need for blood transfusions.
At present, there are over 16 products at various stages for treating PNH. On clinical success, they ought to generate noticeable revenue.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Paroxysmal nocturnal hemoglobinuria (PNH) is a type of clonal disorder that is generally associated with failure of the bone marrow, and in rare instances it may result in leukemia as well.
Age-related clonal hematopoiesis (ARCH) is likely to be the critical link between development of cancer and PNH.
As per the United Nations, percentage of individuals aged 65 and above is expected to rise to 16% by 2050 from 10% in 2022. It further states that the year 2050 is bound to witness twice the number of individuals in the age group of 65 and above the number of children aged 5 and below.
Rise in geriatric population is thus accelerating the paroxysmal nocturnal hemoglobinuria market opportunities.
Biologics is a class of medicines grown in genetically engineered cell cultures. They have reported to transform management of several cancers as well as rare diseases such as paroxysmal nocturnal hemoglobinuria.
Due to increase in spending on prescription drugs coupled with expiry of patents, the manufacturers of drugs have come up with biosimilars, i.e. biologics that are more affordable and analogous to licensed biological therapeutics.
Biosimilars are seen obtaining regulatory approvals across the globe and widening the access of patients to biologics.
Biologics include blood products, hormones, cytokines, vaccines, growth factors, and monoclonal antibodies. They are looked upon as indispensable options regarding treatment of cancer and various other health conditions.
Continual emergence of biologics to cater to therapeutic approaches to paroxysmal nocturnal hemoglobinuria is thus expanding the paroxysmal nocturnal hemoglobinuria market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest paroxysmal nocturnal hemoglobinuria market analysis, North America dominated the paroxysmal nocturnal hemoglobinuria care landscape in 2023 and the dominance is expected to continue during the forecast period. This is attributed to the U.S. witnessing speedy approvals of drugs followed by adoption of new therapies.
Soliris targets the CD5 complement component and dramatically lessens pain linked with symptoms such as abdominal pain, easy bleeding, weakness, dark urine, and fatigue.
Asia Pacific is also holding a decent paroxysmal nocturnal hemoglobinuria market share. Its significant paroxysmal nocturnal hemoglobinuria industry growth is ascribed to Japan witnessing a rising adoption of new therapies.
The prominent players pertaining to treatment for paroxysmal nocturnal hemoglobinuria are devising new products and also working toward upgradation of the existing ones in order to make a mark in the paroxysmal nocturnal hemoglobinuria market.
For instance, in June 2024, Kira Pharmaceuticals presented positive results of KP104 Phase 2 PNH study at the European Hemotology association (EHA) Congress 2024.
Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Genentec, Inc., Novartis AG, The Takeda Pharmaceutical Company Limited, Kira Pharmaceuticals, F. Hoffman-La Roche AG, Akari Therapeutics PLC, Omeros Corporation, and Regeneron Pharmaceuticals, Inc. are some of the key participants covered in the paroxysmal nocturnal hemoglobinuria market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 3.8 Bn |
| Market Forecast (Value) in 2034 | US$ 11.7 Bn |
| Growth Rate (CAGR) | 10.8% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 3.8 Bn in 2023
It is projected to grow at a CAGR of 10.8% from 2024 to 2034
Growing geriatric population and emergence of biologics
Hospitals & clinics segment accounted for the largest share in 2023
North America was the dominant region in 2023
Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Genentec, Inc., Novartis AG, The Takeda Pharmaceutical Company Limited, Kira Pharmaceuticals, F. Hoffman-La Roche AG, Akari Therapeutics PLC, Omeros Corporation, and Regeneron Pharmaceuticals, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paroxysmal Nocturnal Hemoglobinuria Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2020-2034
6.3.1. Medication
6.3.1.1. Eculizumab
6.3.1.2. Ravulizumab
6.3.2. Supplements
6.3.3. Blood Transfusion
6.3.4. Bone Marrow Transplant
6.3.5. Immunosuppressive Therapy
6.4. Market Attractiveness Analysis, by Treatment
7. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals & Clinics
7.3.2. Homecare Settings
7.3.3. Others (Research Institutes, etc.)
7.4. Market Attractiveness Analysis, by End-user
8. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment, 2020-2034
9.3.1. Medication
9.3.1.1. Eculizumab
9.3.1.2. Ravulizumab
9.3.2. Supplements
9.3.3. Blood Transfusion
9.3.4. Bone Marrow Transplant
9.3.5. Immunosuppressive Therapy
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals & Clinics
9.4.2. Homecare Settings
9.4.3. Others (Research Institutes, etc.)
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By End-user
9.6.3. By Country
10. Europe Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment, 2020-2034
10.3.1. Medication
10.3.1.1. Eculizumab
10.3.1.2. Ravulizumab
10.3.2. Supplements
10.3.3. Blood Transfusion
10.3.4. Bone Marrow Transplant
10.3.5. Immunosuppressive Therapy
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals & Clinics
10.4.2. Homecare Settings
10.4.3. Others (Research Institutes, etc.)
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment, 2020-2034
11.3.1. Medication
11.3.1.1. Eculizumab
11.3.1.2. Ravulizumab
11.3.2. Supplements
11.3.3. Blood Transfusion
11.3.4. Bone Marrow Transplant
11.3.5. Immunosuppressive Therapy
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals & Clinics
11.4.2. Homecare Settings
11.4.3. Others (Research Institutes, etc.)
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment, 2020-2034
12.3.1. Medication
12.3.1.1. Eculizumab
12.3.1.2. Ravulizumab
12.3.2. Supplements
12.3.3. Blood Transfusion
12.3.4. Bone Marrow Transplant
12.3.5. Immunosuppressive Therapy
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals & Clinics
12.4.2. Homecare Settings
12.4.3. Others (Research Institutes, etc.)
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment, 2020-2034
13.3.1. Medication
13.3.1.1. Eculizumab
13.3.1.2. Ravulizumab
13.3.2. Supplements
13.3.3. Blood Transfusion
13.3.4. Bone Marrow Transplant
13.3.5. Immunosuppressive Therapy
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals & Clinics
13.4.2. Homecare Settings
13.4.3. Others (Research Institutes, etc.)
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Alexion Pharmaceuticals, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Apellis Pharmaceuticals
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Genentec, Inc.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Novartis AG
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. The Takeda Pharmaceutical Company Limited
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Kira Pharmaceuticals
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. F. Hoffman-La Roche AG
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Akari Therapeutics PLC
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Omeros Corporation
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Regeneron Pharmaceuticals, Inc.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
Table 02: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 03: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 04: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 05: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
Table 06: North America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 07: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
Table 09: Europe Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 10: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 11: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
Table 12: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
Table 15: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by Treatment, 2020-2034
Table 18: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Paroxysmal Nocturnal Hemoglobinuria Market Revenue (US$ Bn), by Treatment, 2023
Figure 03: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by Treatment, 2023
Figure 04: Global Paroxysmal Nocturnal Hemoglobinuria Market Revenue (US$ Bn), by End-user, 2023
Figure 05: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by End-user, 2023
Figure 06: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share, by Region, 2023
Figure 07: Global Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast, 2020-2034
Figure 08: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 09: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
Figure 10: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 11: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
Figure 12: Global Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Region, 2023 and 2034
Figure 13: Global Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Region, 2020-2034
Figure 14: North America Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 15: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country, 2020-2034
Figure 16: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country, 2023 and 2034
Figure 17: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 18: North America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 19: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
Figure 20: North America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
Figure 21: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 22: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 23: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 24: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 25: Europe Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 26: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
Figure 27: Europe Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
Figure 28: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 29: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 30: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 31: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 32: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
Figure 34: Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
Figure 35: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 36: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 37: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 38: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 39: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
Figure 41: Latin America Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
Figure 42: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 43: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 44: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 45: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 46: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 47: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by Treatment, 2020-2034
Figure 48: Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Attractiveness Analysis, by End-user, 2020-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Paroxysmal Nocturnal Hemoglobinuria Market
